Search

Gadoteridol

[A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained … Gadoteridol is a macrocyclic nonionic gadolinium that provides contrast enhancement of the brain, spine, and surrounding tissues, resulting in improved visualization (compared with unenhanced MRI) of lesions

Betahistine

[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It has a significant impact on both the physical and social functioning of affected individuals.

Otilonium

COVID19 s-vax loaded autologous dendritic cell vaccine

The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. … DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19.

Oregovomab

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Bromopride

Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

Methyl-D9-choline

Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

Calcium lactate gluconate

Daclizumab

The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. … 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de

Quinfamide

Quinfamide has been used in trials studying the treatment of Amoebiasis and Helminthiasis.